In assessing the involvement of DNM1L in GC, the Tumor Immunity Estimation Resource (TIMER2.0), the TCGA project database, and the GEO database of the National Center for Biotechnology Information were used to perform comprehensive analysis of whether DNM1L showed different expression levels in patients with GC. This evidence concerns the gene DNM1L and neoplasm.